EUVIMEDEUVIMED entdecken
Crossref

Cost-benefit analysis of pharmacist early active consultation in patients with multidrug-resistant bacteria in China

Xuefeng Shan, Xiaoying Zheng, Hongmei Wang, Lingxi Kong, Youlan Shan, Jie Dong, Jinghui Gou, Guili Huang, Xin Xi, Qian Du

International Journal of Clinical Pharmacy · 2025

DOI: 10.1007/s11096-025-01889-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Xuefeng Shan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Bishan Hospital of Chongqing Medical University, Chongqing, 402760, People's Republic of China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Pharmacists, Drug Resistance, Multiple, Bacterial, Referral and Consultation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Chongqing innovative medical device application demonstration project, Bishan District Science and Technology Bureau of Chongqing, The project in Bishan Hospital of Chongqing--Innovative team building based on evidence-based pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although Pharmacist Early Active Consultation (PEAC) has demonstrated clinical benefits in patients with multidrug-resistant organisms (MDROs), its cost-effectiveness in China remains insufficiently studied. AIM: This study aimed to evaluate the cost-effectiveness of PEAC in patients with MDROs from the perspective of the Chinese healthcare system. METHOD: A historically controlled study was conducted on 100 MDRO-infected patients, including 37 who received PEAC and 63 who did not. The effective treatment rate and duration of the symptoms were assessed. A decision tree model was developed using model inputs derived from the study. The primary endpoints included incremental cost per MDRO treatment and incremental cost-effectiveness ratio (ICER). Uncertainty was evaluated using one-way and probabilistic sensitivity analysis. RESULTS: The effective treatment rate increased to 89.1% in the PEAC group compared with 62.1% in the no-consultation group. Patients in the PEAC group experienced a 2.1-day shorter duration of symptoms than those without consultation (15.5 days vs. 17.6 days, P = 0.04). The base case analysis estimated that the PEAC group gained 0.189 quality-adjusted life years (QALYs) at a cost of $18,209.7, while the no-consultation group gained 0.177 QALYs at a cost of $23,831.1. The PEAC group was more cost-effective, yielding an ICER of - $475,499.0 per QALY gained. Probabilistic sensitivity analysis indicated that PEAC was cost-effective in 60.1% of cases, with costs remaining below the willingness-to-pay (WTP) threshold, supporting PEAC as a cost-effective strategy for managing MDRO infections. CONCLUSION: Pharmacist Early Active Consultation was a more cost-effective strategy than no consultation for treating MDRO infections in patients in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisPharmacistsDrug Resistance, Multiple, BacterialReferral and ConsultationAnti-Bacterial AgentsHumansChinaMaleFemaleMiddle AgedAgedQuality-Adjusted Life YearsAdultProfessional Role

Stichwörter der Autor:innen

Cost-effectivenessDecision-tree modelInfection diseaseMultidrug-resistant organismPharmacist early active consultation

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Bishan Hospital of Chongqing Medical University, Chongqing, 402760, People's Republic of China.
  • Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
  • Department of Infectious Disease, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
  • Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, 1 Shuanghu Branch Rd, Yubei District, Chongqing, 401120, People's Republic of China.
  • Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, 1 Shuanghu Branch Rd, Yubei District, Chongqing, 401120, People's Republic of China. duqian@hospital.cqmu.edu.cn.

Förderung

  • Chongqing innovative medical device application demonstration project
  • Bishan District Science and Technology Bureau of Chongqing
  • The project in Bishan Hospital of Chongqing--Innovative team building based on evidence-based pharmacy
  • Project commissioned by the Pharmaceutical Administration Department of the National Health Commission
  • Chongqing Municipal Health Commission——Senior Medical Talents Program of Chongqing for Young and Middle-aged
  • Chongqing Municipal Health Commission Office——Chongqing Clinical Pharmacy Key Specialties Construction Project(Respiratory medicine specialty)
  • Bishan District Health Commission of Chongqing——Bishan District of Chongqing Clinical Pharmacy Key Specialties Construction Project
  • Chongqing Clinical Pharmacy Key Specialties Construction Project

Zitieren

APA

Shan, X., Zheng, X., Wang, H., Kong, L., Shan, Y., Dong, J., Gou, J., Huang, G., Xi, X., & Du, Q. (2025). Cost-benefit analysis of pharmacist early active consultation in patients with multidrug-resistant bacteria in China. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-01889-0

Vancouver

Shan X, Zheng X, Wang H, Kong L, Shan Y, Dong J, et al. Cost-benefit analysis of pharmacist early active consultation in patients with multidrug-resistant bacteria in China. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-01889-0

BibTeX
@article{Shan2025,
  author = {Shan, Xuefeng and Zheng, Xiaoying and Wang, Hongmei and Kong, Lingxi and Shan, Youlan and Dong, Jie and Gou, Jinghui and Huang, Guili and Xi, Xin and Du, Qian},
  title = {Cost-benefit analysis of pharmacist early active consultation in patients with multidrug-resistant bacteria in China},
  journal = {International Journal of Clinical Pharmacy},
  year = {2025},
  doi = {10.1007/s11096-025-01889-0}
}
Kostenlos starten →